Abstract
In prostate cancer DNA methylation have been recorded as one of the main epigenetic event. More than 50 genes, in fact, have been found hypermethylated in prostate cancer (Li et al., Biochim Biophys Acta 1704:87–102, 2004; Nelson et al., Front Biosci 12:4254–4266, 2007). However, only a small number of genes, e.g. RASSF1A, RARB2, APC, and GSTP1 (Florl et al., Br J Cancer 91:985–994, 2004) or GSTP1, APC and MDR1 (Enokida et al., Clin Cancer Res 11:6582–6588, 2005) can help to discriminate between benign and cancerous changes in the prostate, by hypermethylation assay. The assays for genes hypermethylated in a fraction of the cases may help to distinguish different subgroups of prostate cancer, even if the low sensitivity of the assay is mostly dependent on the amount of DNA obtained by the primary sample (biopsy, serum, urine). Then, the reliability of this tests, unfortunately, is still low (Li et al., Biochim Biophys Acta 1704:87–102, 2004).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aitchison A, Warren A, Neal D, Rabbitts P (2007) RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 67:638–644
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68:6162–6170
Benbrahim-Tallaa L, Waterland RA, Dill AL, Webber MM, Waalkes MP (2007) Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with overexpression of de novo DNA methyltransferase. Environ Health Perspect 115:1454–1459
Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV (2006) Essential role for activation of the polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5:1886–1901
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14:1271–1277
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is down- stream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323–5335
Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC et al (2005) Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 11:6582–6588
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45
Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R et al (2004) Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91:985–994
Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC (2006) Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 12:1412–1419
Guil S, Esteller M (2009) DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 41:87–95
Gunster MJ, Raaphorst FM, Hamer KM, den Blaauwen JL, Fieret E, Meijer CJ et al (2001) Differential expression of human Polycomb group proteins in various tissues and cell types. J Cell Biochem Suppl 36:129–143
Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778–808
Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA (2007) Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 6:1403–1412
Hornstein M, Hoffmann MJ, Alexa A, Yamanaka M, Muller M, Jung V et al (2008) Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer. Cancer Genomics Proteomics 5:123–136
Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF et al (1998) Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58:5310–5314
Koeneman KS, Yeung F, Chung LW (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246–261
Li LC, Okino ST, Dahiya R (2004) DNA methylation in prostate cancer. Biochim Biophys Acta 1704:87–102
Liu L, Zhang J, Bates S, Li JJ, Peehl DM, Rhim JS et al (2005) A methylation profile of in vitro immortalized human cell lines. Int J Oncol 26:275–285
Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S et al (2008) Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134:521–533
Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH et al (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor- dependent transcription. Nature 437:436–439
Morey K Sr, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR (2008) Stage-specific alterations of DNA methyltransferase expression, DNA hyper- methylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res 6:1365–1374
Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M et al (2007) Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 12:4254–4266
Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788–1793
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135
Rajasekhar VK, Begemann M (2007) Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. Stem Cells 25:2498–2510
Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF et al (2008) MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112:4202–4212
Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T (2006) The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45:639–645
Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M (2004) Stem cells and cancer; the polycomb connection. Cell 118:409–418
van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA et al (2007) Polycomb-group oncogenes EZH2, BMI1, and RING1 are over- expressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52:455–463
Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68:9703–9711
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908):1695–1699
Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z et al (2007) JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA 104:19226–19231
Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y et al (2004) Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164:2003–2012
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Celetti, A. (2013). Epigenetic Mechanisms: Histone Acetylation, DNA Methylation, miRNA, Chromatin Modifiers. In: Staibano, S. (eds) Prostate Cancer: Shifting from Morphology to Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7149-9_12
Download citation
DOI: https://doi.org/10.1007/978-94-007-7149-9_12
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7148-2
Online ISBN: 978-94-007-7149-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)